Organisation paid for research Program year 2024 Source: CMS Open Payments

Vanderbilt Univ Medcl Ctr

Neither a doctor nor a teaching hospital

Research payments

$459,990

114 payments

Through program year 2024, Vanderbilt Univ Medcl Ctr is reported as receiving $459,990 in research payments, across 114 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$154,648	47
2023	Research	$122,588	21
2021	Research	$34,794	7
2020	Research	$22,237	13
2019	Research	$125,722	26

Breakdown

Who paid Research payments · program years 2019–2024

Janssen Research & Development, LLC $410,645 112 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $26,421 1 payment
Boehringer Ingelheim Pharma GmbH & Co.KG $22,924 1 payment

Studies the money was for Research payments · program years 2019–2024

A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy $107,190 14 payments
78934804Uco2001 $85,176 43 payments
70033093Str3001 $39,108 3 payments
70033093Acs3003 $35,351 2 payments
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events Hospitalization and Death in Medically Ill Outpatients With Acute Symptomatic Coronavirus Disease 2019 COVID19 Infection $27,860 3 payments
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease $26,849 14 payments
randomized & cetuximab vs afa alone $26,421 1 payment
A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination With Atezolizumab Compared With Atezolizumab Alone in Subjects With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer $23,706 6 payments
#Name? $22,924 1 payment
Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis $21,932 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.